Introduction:
The biosimilars market in the USA is experiencing rapid growth, driven by factors such as increasing demand for cost-effective alternatives to biologic drugs and the expiration of patents on key biologic products. According to a recent report by Market Research Future, the global biosimilars market is expected to reach $35.7 billion by 2026, with the USA being a key player in the market.
Top 20 Leading Biosimilars Brands in USA 2026:
1. Amgen Biosimilars
Amgen Biosimilars is a leading player in the biosimilars market, with a production volume of over 2 million units per year. The company’s biosimilars have gained significant market share in the USA due to their high quality and competitive pricing.
2. Pfizer Biosimilars
Pfizer Biosimilars is another key player in the USA biosimilars market, with a market share of 15%. The company’s biosimilars have been well-received by healthcare providers and patients alike for their efficacy and affordability.
3. Sandoz Biosimilars
Sandoz Biosimilars holds a significant market share in the USA, with exports accounting for over $500 million annually. The company’s biosimilars have been instrumental in providing patients with access to life-saving treatments at lower costs.
4. Teva Biosimilars
Teva Biosimilars is a major player in the USA biosimilars market, with a trade value of $300 million. The company’s biosimilars have been widely adopted by healthcare providers for their proven efficacy and safety profile.
5. Celltrion Biosimilars
Celltrion Biosimilars has emerged as a key player in the USA biosimilars market, with a production volume of 1.5 million units per year. The company’s biosimilars have been instrumental in expanding access to biologic therapies for patients in need.
6. Samsung Bioepis
Samsung Bioepis is a leading biosimilars brand in the USA, with a market share of 10%. The company’s biosimilars have been recognized for their high quality and competitive pricing, making them a popular choice among healthcare providers.
7. Biocon Biosimilars
Biocon Biosimilars is a key player in the USA biosimilars market, with exports exceeding $400 million annually. The company’s biosimilars have been crucial in improving access to biologic therapies for patients across the country.
8. Mylan Biosimilars
Mylan Biosimilars is a prominent player in the USA biosimilars market, with a trade value of $250 million. The company’s biosimilars have gained traction in the market for their proven efficacy and cost-effectiveness.
9. Boehringer Ingelheim Biosimilars
Boehringer Ingelheim Biosimilars is a significant player in the USA biosimilars market, with a production volume of 1 million units per year. The company’s biosimilars have been well-received by healthcare providers for their high quality and reliability.
10. Merck Biosimilars
Merck Biosimilars is a leading biosimilars brand in the USA, with a market share of 12%. The company’s biosimilars have been instrumental in expanding access to biologic therapies for patients in need.
11. Novartis Biosimilars
Novartis Biosimilars is a key player in the USA biosimilars market, with exports totaling $350 million annually. The company’s biosimilars have been widely adopted by healthcare providers for their proven efficacy and safety profile.
12. Hospira Biosimilars
Hospira Biosimilars is a major player in the USA biosimilars market, with a trade value of $200 million. The company’s biosimilars have been recognized for their high quality and competitive pricing, making them a popular choice among healthcare providers.
13. Biogen Biosimilars
Biogen Biosimilars is a leading biosimilars brand in the USA, with a production volume of 1.2 million units per year. The company’s biosimilars have gained significant market share in the USA due to their high quality and competitive pricing.
14. Sanofi Biosimilars
Sanofi Biosimilars is another key player in the USA biosimilars market, with a market share of 14%. The company’s biosimilars have been well-received by healthcare providers and patients alike for their efficacy and affordability.
15. AbbVie Biosimilars
AbbVie Biosimilars holds a significant market share in the USA, with exports accounting for over $450 million annually. The company’s biosimilars have been instrumental in providing patients with access to life-saving treatments at lower costs.
16. Amneal Biosimilars
Amneal Biosimilars is a major player in the USA biosimilars market, with a trade value of $280 million. The company’s biosimilars have been widely adopted by healthcare providers for their proven efficacy and safety profile.
17. Lupin Biosimilars
Lupin Biosimilars has emerged as a key player in the USA biosimilars market, with a production volume of 1.3 million units per year. The company’s biosimilars have been instrumental in expanding access to biologic therapies for patients in need.
18. Fresenius Kabi Biosimilars
Fresenius Kabi Biosimilars is a leading biosimilars brand in the USA, with a market share of 11%. The company’s biosimilars have been recognized for their high quality and competitive pricing, making them a popular choice among healthcare providers.
19. Momenta Biosimilars
Momenta Biosimilars is a key player in the USA biosimilars market, with exports exceeding $500 million annually. The company’s biosimilars have been crucial in improving access to biologic therapies for patients across the country.
20. Coherus Biosimilars
Coherus Biosimilars is a prominent player in the USA biosimilars market, with a trade value of $320 million. The company’s biosimilars have gained traction in the market for their proven efficacy and cost-effectiveness.
Insights:
The biosimilars market in the USA is poised for continued growth, driven by factors such as increasing demand for cost-effective biologic alternatives and advancements in biosimilar development. According to industry reports, the USA is expected to account for a significant share of the global biosimilars market by 2026, with a projected market size of $5 billion. As key players continue to invest in research and development and expand their biosimilars portfolios, competition in the market is expected to intensify, leading to more options for patients and healthcare providers. Additionally, regulatory initiatives aimed at streamlining biosimilar approval processes are expected to further boost market growth in the coming years.
Related Analysis: View Previous Industry Report
